XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1031-1037

  Chung, Hyun Hoon ^a   Kim, Mi Kyung ^a   Kim, Jae Weon ^a   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a   Lee, Hyo Pyo ^a  

^a Seoul National University   (South Korea)

Author keywords

MDR analysis; Neoadjuvant chemotherapy; Polymorphism; Response; XRCC1

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GAMMA GLUTAMYL HYDROLASE; GENE PRODUCT; GLUTATHIONE TRANSFERASE; METHYLTETRAHYDROFOLATE REDUCTASE; PLATINUM DERIVATIVE; REDUCED FOLATE CARRIER; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; EXCISION REPAIR CROSS COMPLEMENTING GENE; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LINEAR SYSTEM; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MEDICAL RECORD; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN PROTEIN INTERACTION; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE FIXATION; TISSUE SECTION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; X RAY REPAIR CROSS COMPLEMENTING GENE 1;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; HUMANS; HYSTERECTOMY; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 33751425930     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.016     Document Type: Article

References (44)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Sardi J.E., di Paola G.R., Cachau A., Ortiz O.C., Sananes C., Giaroli A., et al. A possible new trend in the management of the carcinoma of the cervix uteri. Gynecol. Oncol. 25 (1986) 139-149
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
4. Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350 (1997) 535-540
5. Piver M.S., and Chung W.S. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet. Gynecol. 46 (1975) 507-510
6. Delgado G., Bundy B.N., Fowler Jr. W.C., Stehman F.B., Sevin B., Creasman W.T., et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol. Oncol. 35 (1989) 314-320
7. Lai C.H., Hsueh S., Huang M.Y., Chang M.F., and Soong Y.K. The uses and limitations of DNA flow cytometry in stage IB or II cervical carcinoma. Cancer 72 (1993) 3655-3662
8. Panici P.B., Scambia G., Baiocchi G., Greggi S., Ragusa G., Gallo A., et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer 67 (1991) 372-379
9. Namkoong S.E., Park J.S., Kim J.W., Bae S.N., Han G.T., Lee J.M., et al. Comparative study of the patients with locally advanced stages I and II cervical cancer treated by radical surgery with and without preoperative adjuvant chemotherapy. Gynecol. Oncol. 59 (1995) 136-142
10. Eddy G.L., Manetta A., Alvarez R.D., Williams L., and Creasman W.T. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol. Oncol. 57 (1995) 412-416
11. Sardi J., Sananes C., Giaroli A., Bayo J., Rueda N.G., Vighi S., et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol. Oncol. 49 (1993) 156-165
12. Chang H.C., Lai C.H., Chou P.C., Tseng C.J., Chang T.C., Hsueh S., et al. Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma. Cancer Chemother. Pharmacol. 30 (1992) 281-285
13. Lai C.H., Hsueh S., Chang T.C., Tseng C.J., Huang K.G., Chou H.H., et al. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol. Oncol. 64 (1997) 456-462
14. Tseng C.J., Tseng L.H., Lai C.H., Soong Y.K., Hsueh S., and Pao C.C. Identification of human papillomavirus types 16 and 18 deoxyribonucleic acid sequences in bulky cervical cancer after chemotherapy. Am. J. Obstet. Gynecol. 176 (1997) 865-869
15. Konishi I., Nanbu K., Mandai M., Tsuruta Y., Kataoka N., Nagata Y., et al. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol. Oncol. 70 (1998) 365-371
16. Li Y., Marion M.J., Rundle A., and Brandt-Rauf P.W. A common polymorphism in XRCC1 as a biomarker of susceptibility for chemically induced genetic damage. Biomarkers 8 (2003) 408-414
17. Alberola V., Sarries C., Rosell R., Taron M., de las Penas R., Camps C., et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer 5 (2004) 360-365
18. Sarbia M., Stahl M., von Weyhern C., Weirich G., and Puhringer-Oppermann F. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br. J. Cancer 94 (2006) 203-207
19. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94 (2006) 281-286
20. Beeghly A., Katsaros D., Chen H., Fracchioli S., Zhang Y., Massobrio M., et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol. Oncol. 100 (2006) 330-337
21. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 1 (2005) 6212-6217
22. Efferth T., and Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 107 (2005) 155-176
23. Aplenc R., Thompson J., Han P., La M., Zhao H., Lange B., et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res. 65 (2005) 2482-2487
24. Allan J.M., Smith A.G., Wheatley K., Hills R.K., Travis L.B., Hill D.A., et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 (2004) 3872-3877
25. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44 (2004) 311-316
26. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22 (2004) 2594-2601
27. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15 (2004) 1194-1203
28. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91 (2004) 344-354
29. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10 (2004) 4939-4943
30. Rosell R., Lord R.V., Taron M., and Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38 (2002) 217-227
31. Wei Q., Frazier M.L., and Levin B. DNA repair: a double-edged sword. J. Natl. Cancer Inst. 92 (2000) 440-441
32. Niwa Y., Matsuo K., Ito H., Hirose K., Tajima K., Nakanishi T., et al. Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol. Oncol. 99 (2005) 43-49
33. Lunn R.M., Langlois R.G., Hsieh L.L., Thompson C.L., and Bell D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59 (1999) 2557-2561
34. Duell E.J., Wiencke J.K., Cheng T.J., Varkonyi A., Zuo Z.F., Ashok T.D., et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21 (2000) 965-971
35. Matullo G., Palli D., Peluso M., Guarrera S., Carturan S., Celentano E., et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22 (2001) 1437-1445
36. Matullo G., Guarrera S., Carturan S., Peluso M., Malaveille C., Davico L., et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int. J. Cancer 92 (2001) 562-567
37. Hu J.J., Smith T.R., Miller M.S., Mohrenweiser H.W., Golden A., and Case L.D. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22 (2001) 917-922
38. Rothem L., Aronheim A., and Assaraf Y.G. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J. Biol. Chem. 278 (2003) 8935-8941
39. Rothem L., Stark M., Kaufman Y., Mayo L., and Assaraf Y.G. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J. Biol. Chem. 279 (2004) 374-384
40. Rothem L., Stark M., and Assaraf Y.G. Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol. Pharmacol. 66 (2004) 1536-1543
41. Laverdiere C., Chiasson S., Costea I., Moghrabi A., and Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100 (2002) 3832-3834
42. Moore J.H., and Williams S.M. New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34 (2002) 88-95
43. Ritchie M.D., Hahn L.W., and Moore J.H. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet. Epidemiol. 24 (2003) 150-157
44. Hahn L.W., Ritchie M.D., and Moore J.H. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19 (2003) 376-382